65
Participants
Start Date
December 21, 2018
Primary Completion Date
July 5, 2022
Study Completion Date
July 5, 2022
AP10-602
Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
Malaria challenge
Exposure to mosquitoes infected with P. falciparum.
rCSP
The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID)
NIH